Abstract | INTRODUCTION: METHODS: RESULTS: An increased prevalence of certain class II alleles was associated with the presence of anti-Ro/ SS-A antibodies as follows: DRB1*08:03 (Pc = 3.79×10(-5), odds ratio [OR] 3.06, 95% confidence interval [CI] 1.98-4.73), DQB1*06:01 (Pc = 0.0106, OR 1.70, 95%CI 1.26-2.31), and DPB1*05:01 (Pc = 0.0040, OR 1.55, 95%CI 1.23-1.96). On the other hand, DRB1*15:01 (Pc = 0.0470, OR 3.14, 95%CI 1.63-6.05), DQB1*06:02 (Pc = 0.0252, OR 3.14, 95%CI 1.63-6.05), and DPB1*05:01 (Pc = 0.0069, OR 2.27, 95% CI 1.44-3.57) were associated with anti-La/SS-B antibodies. The DPB1*05:01 allele was associated with anti-Ro/SS-A (Pc = 0.0408, OR 1.69, 95% CI 1.19-2.41) and anti-La/SS-B antibodies (Pc = 2.48×10(-5), OR 3.31, 95%CI 2.02-5.43) in SLE patients. CONCLUSION:
|
Authors | Hiroshi Furukawa, Shomi Oka, Kota Shimada, Shoji Sugii, Atsushi Hashimoto, Akiko Komiya, Naoshi Fukui, Tatsuo Nagai, Shunsei Hirohata, Keigo Setoguchi, Akira Okamoto, Noriyuki Chiba, Eiichi Suematsu, Taiichiro Miyashita, Kiyoshi Migita, Akiko Suda, Shouhei Nagaoka, Naoyuki Tsuchiya, Shigeto Tohma |
Journal | PloS one
(PLoS One)
Vol. 8
Issue 1
Pg. e53910
( 2013)
ISSN: 1932-6203 [Electronic] United States |
PMID | 23320107
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Antinuclear
- HLA-DP beta-Chains
- HLA-DPB1 antigen
- HLA-DPB1*05:01 antigen
- HLA-DQ beta-Chains
- HLA-DQbeta antigen
- HLA-DRB1 Chains
- SS-A antibodies
- SS-B antibodies
|
Topics |
- Aged
- Antibodies, Antinuclear
(blood)
- Arthritis, Rheumatoid
(genetics, immunology)
- Asian People
(genetics)
- Case-Control Studies
- Female
- Gene Frequency
- Genes, MHC Class II
- Genetic Association Studies
- HLA-DP beta-Chains
(genetics)
- HLA-DQ beta-Chains
(genetics)
- HLA-DRB1 Chains
(genetics)
- Humans
- Japan
- Lupus Erythematosus, Systemic
(genetics, immunology)
- Male
- Middle Aged
- Sjogren's Syndrome
(genetics, immunology)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|